Innovating Antibodies, Transforming Lives
Akeso, Inc (康方生物) (akesobio.com) scores 71 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 26th percentile of 13268 Healthcare brands.
Akeso, Inc. (康方生物) is a biopharmaceutical company focused on developing first-in-class and best-in-class antibody-based drugs. Using its proprietary ACE Platform, which integrates AI drug discovery, bispecific/multispecific antibodies, ADC, TCE, siRNA, cell therapy, and circular RNA technologies, Akeso creates innovative therapies for cancer, autoimmune disorders, respiratory and CNS conditions, inflammation, and metabolic diseases. The company combines international R&D expertise with GMP manufacturing and commercialization capabilities to serve patients, healthcare providers, and biopharmaceutical partners worldwide.
| Brand Name | Akeso, Inc (康方生物) |
|---|---|
| Domain | akesobio.com |
| Industry | Healthcare |
| Main Competitors | Innovent Biologics (67/100), BeiGene (85/100), Junshi Biosciences (68/100), Hengrui Pharmaceuticals (62/100), Zai Lab (77/100), Regeneron Pharmaceuticals (92/100), Merck & Co. (81/100) |
Moz Domain Authority 30/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #2,118,385 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "To develop first-in-class and best-in-class innovative drugs that provide affordable antibody-based solutions to patients worldwide." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Content is CN-only, limiting citation in English-language AI answers.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Akeso, Inc (康方生物)?", Claude could identify the brand as of October 2026. Akeso is a Chinese biopharmaceutical company based in Zhongshan/Hong Kong that develops innovative antibody-based drugs, especially bispecific antibodies and immuno-oncology therapies. It's best known for developing cadonilimab (Kaitanni), the world's first approved PD-1/CTLA-4 b Best known for Developing cadonilimab and ivonescimab, pioneering bispecific antibody cancer immunotherapies.
When asked "Best brands similar to Akeso, Inc (康方生物)?", Claude would recommend Akeso, Inc (康方生物) as of October 2026. Akeso is a notable and increasingly prominent Chinese biotech known for cutting-edge bispecific antibody drugs, making it relevant when discussing leading oncology biotech companies, especially from China.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Akeso, Inc (康方生物)'s main competitors in Healthcare: Innovent Biologics (67/100), BeiGene (85/100), Junshi Biosciences (68/100), Hengrui Pharmaceuticals (62/100), Zai Lab (77/100).
Sources: Brand Analyzer scan
Akeso, Inc (康方生物) has low AI-search visibility, scoring 14/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 19, recommendation 32). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Akeso, Inc (康方生物) official site
Akeso offers antibody-based drug therapies developed through its ACE Platform, which includes bispecific and multispecific antibodies, antibody-drug conjugates (ADC), T-cell engagers (TCE), siRNA-based therapies, cell therapy products, and circular RNA technologies. These products target diseases such as cancer, autoimmune disorders, respiratory and central nervous system conditions, inflammation, and metabolic diseases.
Sources: Akeso, Inc (康方生物) official site
Akeso, Inc (康方生物) scores 32/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Akeso, Inc (康方生物) official site
Akeso, Inc. (康方生物) is a biopharmaceutical company that develops innovative, antibody-based drugs. It focuses on creating first-in-class and best-in-class therapies for major diseases including cancer, autoimmune disorders, respiratory and central nervous system conditions, inflammation, and metabolic diseases. The company operates globally, combining R&D, manufacturing, and commercialization capabilities to deliver its products to patients and healthcare partners.
Sources: Akeso, Inc (康方生物) official site
Akeso develops antibody-based drugs using its proprietary ACE Platform, which integrates technologies such as AI-driven drug discovery, bispecific and multispecific antibodies, antibody-drug conjugates (ADC), T-cell engagers (TCE), siRNA, cell therapy, and circular RNA. The company researches, manufactures, and commercializes these therapies to address unmet clinical needs in oncology, autoimmune disease, respiratory and CNS conditions, inflammation, and metabolic disorders.
Sources: Akeso, Inc (康方生物) official site
Akeso, Inc (康方生物) can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Akeso, Inc (康方生物) official site
Akeso is known for its proprietary ACE Platform, an integrated system combining multiple advanced biotechnologies-including bispecific/multispecific antibodies, ADC, TCE, siRNA, cell therapy, AI drug discovery, and circular RNA-used to develop innovative antibody-based drugs for major diseases such as cancer and autoimmune disorders.
Sources: Akeso, Inc (康方生物) official site
Akeso's products and services are intended for patients worldwide suffering from major diseases such as cancer, autoimmune disorders, respiratory and central nervous system conditions, inflammation, and metabolic diseases. The company also works with healthcare providers and biopharmaceutical partners who collaborate on research, development, and commercialization of its therapies.
Sources: Akeso, Inc (康方生物) official site
Akeso, Inc (康方生物) scores 14/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Akeso, Inc (康方生物) has a weak AI-visibility profile at 14/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (32/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #2,118,385 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 30/100. In a live check, Claude could already identify Akeso, Inc (康方生物) from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Akeso, Inc (康方生物): AIQ Global (71/100), AHIS (71/100), ALIGNERCO (71/100), Australian Medical Association (AMA) (71/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.